Related Experiment Video
Updated: Aug 7, 2026

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
Is intralesional cidofovir worthwhile in juvenile recurrent respiratory papillomatosis?
P Sheahan1, S Sexton, J D Russell
1Department of Otorhinolaryngology-Head and Neck Surgery, Our Lady's Hospital for Sick Children, Crumlin, Dublin, Ireland. sheahanp@eircom.net
Insights
Intralesional cidofovir shows promise in managing recurrent respiratory papillomatosis (RRP) in children, reducing disease severity and controlling regrowth. However, it is less effective for complete eradication and prolonged treatment beyond eight injections may not be beneficial.
Area of Science:
- Pediatric Otolaryngology
- Viral Infections
- Oncology
Background:
- Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease caused by human papillomavirus (HPV).
- RRP poses significant challenges in pediatric management due to potential airway obstruction and frequent surgical interventions.
Purpose of the Study:
- To evaluate the effectiveness of intralesional cidofovir as a treatment for RRP in pediatric patients.
- To assess the impact of cidofovir on disease severity and papilloma regrowth.
Main Methods:
- Prospective observational study involving four children with RRP.
- Treatment included surgical debulking followed by intralesional cidofovir injections.
- Disease severity was monitored using an anatomical RRP severity score and photodocumentation.
Main Results:
- One patient achieved complete remission; two showed partial response.
- Deterioration was observed when treatment was paused, with subsequent improvement upon resumption.
- A plateau in efficacy was noted by the eighth cidofovir injection.
Conclusions:
- Intralesional cidofovir can help control RRP and reduce disease severity in children.
- Cidofovir appears less effective for complete disease eradication.
- Evidence suggests limited benefit from prolonged treatment regimens exceeding eight injections.
Objective:
To investigate the efficacy of intralesional cidofovir in the treatment of recurrent respiratory papillomatosis (RRP) in children.
Methods:
Prospective observational study of four consecutive children with RRP treated at an academic tertiary children's hospital. Laryngo-bronchoscopy was performed at three- to five-weekly intervals. Photodocumentation was obtained and disease severity assessed using an anatomical RRP severity score. Surgical debulking of large papillomas was then performed, and cidofovir (5 mg/ml) injected into any remaining papillomas as well as submucosally at the sites of resected papillomas. The efficacy of cidofovir was assessed by the change in papilloma severity score over the course of the treatment.
Results:
Complete disease remission was obtained in one patient, with a partial response seen in two others. One patient showed no significant response. The greatest beneficial effect was seen after the fourth cidofovir injection; however, two patients demonstrated a deterioration in severity scores after treatment was withheld at this point. Both responded well to further cidofovir injections. However, a clear plateau in the response to cidofovir was seen in all patients by the eighth injection.
Conclusion:
Intralesional cidofovir may help control papilloma regrowth and reduce disease severity in many children with RRP. In most cases, cidofovir would appear to be less efficacious in causing disease eradication. There appears to be little evidence to support prolonged treatment regimes (i.e. more than eight treatments).
Related Concept Videos
Respiratory Syncytial Virus Disease
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cytomegalovirus Disease
Genital Herpes
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Antiviral Nucleoside Inhibitors